Clinical Trials Sponsored by C8Sciences

Total 12579 results

Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Chronic Hepatitis B

Italy, United Kingdom, United States, Taiwan, Korea, Republic of, Canada, New Zealand, Hong Kong
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Gilead Sciences

Completed

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States, Puerto Rico, New Zealand
Gilead Sciences

Completed

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection

United States, France
Gilead Sciences

Completed

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

HIV Infections | HIV

United States, Netherlands, Spain, Mexico, France, Thailand, Australia, United Kingdom, Dominican Republic
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Gilead Sciences

Terminated

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, Canada, Germany
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Gilead Sciences

Completed

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Long QT Syndrome

United States, Romania, New Zealand, Germany
Gilead Sciences

Completed

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Chronic Hepatitis B

Korea, Republic of, Canada, United States, New Zealand, Italy, Romania
Gilead Sciences

Terminated

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

Hepatitis B

Spain, Italy, United Kingdom, Romania, Belgium, France, Greece
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Colorectal Cancer

Spain, United States, Germany, Italy, Russian Federation, Poland, France
Gilead Sciences

Completed

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

Chronic Lymphocytic Leukaemia

United Kingdom, Ireland
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, France, Poland, Ukraine, Switzerland, Romania, Canada, Netherlands, Korea, Republic of, Belgium, Russian Federation, Taiwan, New Zealand, Hungary, United Kingdom, Bulgaria, Latvia, Czechia, Slovakia, Italy and more
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland
Gilead Sciences

Terminated

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH)

Liver Fibrosis Due to NASH

United States, Canada, France, Italy, Germany, Puerto Rico, Spain, United Kingdom
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Hepatitis C Virus Infection

Japan
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Hepatitis C Virus Infection

United States
Gilead Sciences

Terminated

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

Spain, Korea, Republic of, United States, Germany, Canada, France, United Kingdom
Gilead Sciences

Withdrawn

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Diffuse Large B-Cell Lymphoma | Mediastinal B-cell Lymphoma

Italy, Spain, France, Poland
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Canada, Spain, Australia, Italy, United Kingdom, Belgium, Croatia, France, Hungary, Poland, Romania, Czechia
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Hepatitis C Virus Infection

United States, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Terminated

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Hepatitis C Virus Infection

Japan
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

Japan
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Hong Kong, United States, France, Canada, Germany, United Kingdom, Belgium, Italy, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Bridalveil)

Indolent Non-Hodgkin's Lymphomas

United States, Korea, Republic of, Canada, Spain, Taiwan, France, Australia, United Kingdom, Poland, Italy, Israel, Czechia, Germany, Russian Federation, Sweden
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (ASTRAL-3)

Hepatitis C Virus Infection

United States, France, New Zealand, Canada, Germany, Puerto Rico, United Kingdom, Australia, Italy
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
Gilead Sciences

Completed

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (Co-STARs)

HIV-1 Infection | HCV Infection

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

HIV-1 Infection

Spain, United Kingdom, France, Germany, United States, Italy
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Hepatitis C Virus Infection

Spain, Switzerland, United Kingdom
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Respiratory Syncytial Virus Infection

United States, France, Sweden, Korea, Republic of, Switzerland
Parion Sciences

Terminated

Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States

3

Subscribe